Disposition of a novel and potent αvβ3 antagonist in animals, and extrapolation to man

Xenobiotica

Volumn 34, Issue 1, 2004, Pages 103-115

  Prueksaritanont, T ^a   Fernandez Metzler, C ^a   Meng, Y ^a   Barrish, A ^a   Halczenko, W ^a   Rodan, S B ^a   Hutchinson, J H ^a   Duggan, M E ^a   Lin, J H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 OXO 3 [3 (5,6,7,8 TETRAHYDRO[1,8]NAPHTHYRIDIN 2 YL)PROPYL]IMIDAZOLIDIN 1 YL] 3 (6 METHOXYPYRIDIN 3 YL)PROPIONIC ACID; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ALLOMETRY; ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG TRANSFORMATION; DRUG URINE LEVEL; HUMAN; MONKEY; MOUSE; NONHUMAN; PREDICTION; RADIOACTIVITY; RAT;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PROTEINS; CARBON RADIOISOTOPES; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; FORECASTING; HUMANS; INFUSIONS, INTRAVENOUS; INTEGRIN ALPHAVBETA3; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE; MICE; NAPHTHYRIDINES; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SUCCINIMIDES;

ANIMALIA; CANIS FAMILIARIS;

EID: 0442329205     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250412331294742     Document Type: Article

References (22)

1. AYRTON, A. and MORGAN, P., 2001, Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica, 31, 469-497.
2. BENET, L. Z. and GALEAZZI, R. L., 1971, Noncompartmental determination of the steady-state volume of distribution. Journal of Pharmaceutical Sciences, 68, 1071-1074.
3. BOXENBAUM, H., 1979, Interspecies variation in liver weight, hepatic blood flow and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmacology, 8, 165-176.
4. BOXENBAUM, H., 1982, Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmacology, 10, 201-227.
5. COLEMAN, P., ASKEW, B., HUTCHINSON, J., WHITMAN, D., PERKINS, J., HARTMAN, G., RODAN, G., LEU, C., PRUEKSARITANONT, T., FERNANDEZ-METZLER, C., MERKLE, K., LYNCH, R., LYNCH, J., RODAN, S. and DUGGAN, M., 2002, Non-peptide alpha(v)beta(3) antagonists. Part 4: Potent and orally bioavailable chain-shortened RGD mimetics. Bioorganic and Medical Chemistry Letters, 12, 2463-2466.
6. CRIPPES, B. A., ENGLEMAN, V. W., SETTLE, S. L., DELARCO, J., ORNBERG, R. L., HELFRICH, M. H., HORTON, M. A. and NICKOLS, G. A., 1998, Antibody to β3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology, 137, 918-924.
7. ENGLEMAN, V. W., NICKOLS, G. A., ROSS, F. P., HORTON, M. A., GRIGGS, D. W., SETTLE, S. L., RUMINSKI, P. G. and TEITELBAUM, S. L., 1997, A peptidomimetic antagonist of the V3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. Journal of Clinical Investigation, 99, 2284-2292.
8. HARTMAN, G. D. and DUGGAN, M. E., 2000, Alpha (v) beta (3) integrin antagonists as inhibitors of bone resorption. Expert Opinion on Investigational Drugs, 9, 1281-1291.
9. 3 antagonist for the prevention of osteoporosis. Paper 223 presented at the ACS National Meeting, Boston, MA, August 2002.
10. KEENAN, R. M., MILLER, W. H., KWON, C., ALI, F. E., CALLAHAN, J. F., CALVO, R. R., HWANG, S.-M., KOPPLE, K. D., PEISHOFF, C. E., SAMANEN, J. M., WONG, A. S., YUAN, C.-K. and HUFFMAN, W. F., 1997, Discovery of potent nonpeptide vitronectin receptor (v3) antagonists. Journal of Medical Chemistry, 40, 2289-2292.
11. KEENAN, R. M., MILLER, W. H., LAGO, M. A., ALI, F. E., BONDINELL, W. E., CALLAHAN, J. F., CALVO, R. R., COUSINS, R. D., HWANG, S.-M., JAKAS, D. R., KU, T. W., KWON, C., NGUYEN, T. T., READER, V. A., RIEMAN, D. J., ROSS, S. T., TAKATA, D. T., UZINSKAS, I. N., YUAN, C.-K. and SMITH, B. R., 1998, Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (v3) antagonists. Bioorganic and Medical Chemistry Letters, 8, 3165-3170.
12. LARK, M. W., STROUP, G. B., HWANG, S.-M., JAMES, I. E., RIEMAN, D. J., DRAKE, F. H., BRADBEER, J. N., MATHUR, A., ERHARD, K. F., NEWLANDER, K. A., ROSS, S. T., SALYERS, K. L., SMITH, B. R., MILLER, W. H., HUFFMAN, W. F. and GOWEN, M., 1999, Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis. Journal of Pharmacology and Experimental Therapeutics, 291, 612-617.
13. MAHMOOD, I. and BALIAN, J. D., 1996, Interspecies scaling: predicting clearance of drugs in humans: three different approaches. Xenobiotica, 26, 887-895.
14. MILLER, W. H., BONDINELL, W. E., COUSINS, R. D., ERHARD, K. F., JAKAS, D. R., KEENAN, R. M., KU, T. W., NEWLANDER, K. A., ROSS, S. T., HALTIWANGER, R. C., BRADBEER, J., DRAKE, F. H., GOWEN, M., HOFFMAN, S. J., HWANG, S.-M., JAMES, I. E., LARK, M. W., LECHOWSKA, B., RIEMAN, D. J., STROUP, G. B., Vasko-MOSER, J. A., ZEMBRYKI, D. L., AZZARANO, L. M., ADAMS, P. C., SALYERS, K. L., SMITH, B. R., WARD, K. W., JOHANSON, K. O. and HUFFMAN, W. F., 1999, Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorganic and Medical Chemistry Letters, 9, 1807-1812.
15. 3 (the vitronectin receptor). Drug Discovery Today, 5, 397-408.
16. OIE, S. and TOZER, T. N., 1979, Effect of altered plasma protein on apparent volume of distribution. Journal of Pharmaceutical Sciences, 68, 1203-1205.
17. 3 antagonists in rats: limited role of P-glycoprotein. Xenobiotica, 32, 207-220.
18. 3 integrin is a powerful inhibitor of bone resorption in vivo. Bone and Mineral Research, 17, S198.
19. SAWADA, Y., HANANO, M., SUGIYAMA, Y. and IGA, T., 1984, Prediction of the disposition of β-lactam antibiotics in humans from pharmacokinetic parameters in animals. Journal of Pharmacokinetics and Biopharmacology, 12, 241-260.
20. WILKINSON, G. R. and SHANE, D. G., 1975, A physiological approach to hepatic drug clearance. Clinical and Pharmacology Therapy, 18, 377-390.
21. YAMAMOTO, M., FISHER, J. E., GENTILE, M., SEEDOR, J. G., LEU, C.-T., RODAN, S. B. and RODAN, G. A., 1998, The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology, 139, 1411-1419.
22. YANO, I., ITO, T., TAKANO, M. and INUI, K., 1997, Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. Pharmacology Research, 14, 508-511.